| Budget Amount *help |
¥131,430,000 (Direct Cost: ¥101,100,000、Indirect Cost: ¥30,330,000)
Fiscal Year 2022: ¥28,860,000 (Direct Cost: ¥22,200,000、Indirect Cost: ¥6,660,000)
Fiscal Year 2021: ¥28,860,000 (Direct Cost: ¥22,200,000、Indirect Cost: ¥6,660,000)
Fiscal Year 2020: ¥28,860,000 (Direct Cost: ¥22,200,000、Indirect Cost: ¥6,660,000)
Fiscal Year 2019: ¥28,860,000 (Direct Cost: ¥22,200,000、Indirect Cost: ¥6,660,000)
Fiscal Year 2018: ¥15,990,000 (Direct Cost: ¥12,300,000、Indirect Cost: ¥3,690,000)
|
|---|
| Outline of Final Research Achievements |
The results of using chemo-technology include: obtaining compounds that bind to the ubiquitin receptor of the proteasome, obtaining compounds that inhibit proteasome formation, identifying compounds that are synthetic lethal with proteasome inhibitors, creating PROTAC to artificially induce mitophagy, and obtaining monobody against optineurin, which led to the elucidation of new functions of optineurin. During these studies, we also discovered a new mechanism for regulating proteasome expression, liquid droplet formation as a new degradation mechanism by the proteasome, and the ubiquitination-deubiquitination cycle, which is important for ribosome recycling.
|
